The pharmaceutical industry finds itself at a pivotal juncture, marked by a significant transformation in drug approvals. According to insights from the CPHI Annual Industry Survey, approvals for complex molecules are poised to surpass those for small molecules for the first time. This shift
Sutro Biopharma, Inc. has caught the eye of institutional investors recently, marking a significant development in the clinical-stage oncology company's journey. With its innovative approach to developing antibody-drug conjugates (ADCs) using proprietary platforms, Sutro Biopharma has seen a
Eli Lilly's continued advancements in pharmaceutical innovation and their commitment to escalating manufacturing capabilities encapsulate the core of the company's recent endeavors. At the heart of these developments is Eli Lilly’s extensive investment in research and development and the s
LakeShore Biopharma Co Ltd. (NASDAQ: LSB) has attracted significant attention in the stock market due to its highly volatile performance over the past year. Investors have witnessed dramatic shifts in the company's stock price, reflecting a mixed sentiment among stakeholders about the
Wilson County, located in Eastern North Carolina, has recently become a hotspot for significant economic development, largely driven by substantial investments from pharmaceutical giants. Within the past eight days, the region has received promises of major funding, hinting at a promising future
Johnson & Johnson (J&J) has announced plans to construct a state-of-the-art biologics plant in Wilson, North Carolina, with construction set to commence in the first half of 2025. This ambitious project comes with a substantial investment exceeding $2 billion, aimed at bolstering
